Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abatacept for GVHD Prophylaxis in Double Umbilical Cord Blood Transplants
NCT06680661Phase 2Suspended
- Start
- Apr 2026
- Primary completion
- Oct 2027
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in graft-versus-host disease (GVHD). Primary endpoint: Severe Acute Graft Versus Host Disease-Free Survival at 180 days. Started Apr 2026; status: suspended.
02
Drugs
abatacept
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT06680661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680661.